For more than 70 years, polymer specialist Raumedic has partnered with companies and practitioners to develop solutions for medical and pharmaceutical applications.
David Budd, CEO of genedrive says adoption of point of care genetic testing in emergency settings will help save lives and money. However, innovators need to work to persuade healthcare funders to adopt these life-saving technologies.
Ahead of World Stroke Day, David Budd, CEO of genedrive plc, underscores the growing role of pharmacogenetics in personalised medicine and how its application can decrease the odds of secondary cerebrovascular disease.
Rebekah Jordan sits down with Oliver Schacht, CEO of OpGen, to discuss the increasing prevalence of antibiotic resistance in Urinary Tract Infections (UTIs), and how OpGen’s Unyvero can quicken the AR diagnosis process.
Brice Ezzouaouy, senior product manager at Beckman Coulter Life Sciences, looks at the journey of the 2017 IVD Regulation and how it affects different aspects of the industry.
For World Heart Day Ian Bolland speaks to Johnson & Johnson and the University of Leicester about the effects of Atrial Fibrillation on healthcare systems and the technologies and measures that can be put into place to treat the condition.
Med-Tech Innovation editor Ian Bolland speaks to Lionel Maritan, associate director – research and development Becton Dickinson (BD), about the company’s Intevia 2.25ml autoinjector which is set to launch at the end of 2021 or the start of 2022.
Ursula Nollenberger, product line director and Kevin Ehlert, segment manager, Trelleborg Healthcare & Medical discuss the necessary steps to launching a succesful drug/device combination product.
Elizma Parry - director, Global Clinical Practice at Maetrics explains what pharmaceutical manufacturers should be doing to prepare for new and important regulations surrounding medical devices.
As we enter the winter flu season, embracing more innovative diagnostics at the point of care (POC) could play a vital role in helping to address the burden which influenza places on public health services.
In this online exclusive, David Fraser, product manager Lateral Flow Services at BBI Solutions, discusses how easily-accessible diagnostic options could help lessen the burden on global health services.
As a result of the outcomes of a trial comparing two drug-coated balloon (DCB) devices, in which no statistically significant patency rate difference was found, GlobalData, has indicated a potential change in the competitive landscape
